Paper36924123
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.
Yang T and 5 others. Clin Mol Hepatol, 2023. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences. Papers, record 36924123. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36924123
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| East Asian People | |
| China | |
| Hepatectomy |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 81972726 | National Natural Science Foundation of China | PubMed | ||
| 82273074 | National Natural Science Foundation of China | PubMed | ||
| 21SG36 | Dawn Project Foundation of Shanghai | PubMed | ||
| 2022XD001 | Shanghai Health Academic Leader Program | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 36545708 | Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. | https://conductscience.org/library/papers/36545708 |
Source PubMed
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36545708 | Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/36545708 | PubMed |
| 2 | 28634137 | Comparison of Patterns and Outcomes of Liver Resection for Hepatocellular Carcinoma: East vs West. | Clin Gastroenterol Hepatol | 2017 | https://conductscience.org/library/papers/28634137 | PubMed |
| 3 | 32707225 | aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. | J Hepatol | 2020 | https://conductscience.org/library/papers/32707225 | PubMed |
| 4 | 25722082 | Liver disease in China: A long way to go. | Hepatology | 2015 | https://conductscience.org/library/papers/25722082 | PubMed |
| 5 | 25752327 | Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. | Liver Int | 2015 | https://conductscience.org/library/papers/25752327 | PubMed |
| 6 | 30319983 | Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). | Liver Cancer | 2018 | https://conductscience.org/library/papers/30319983 | PubMed |
| 7 | 30909504 | Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30909504 | PubMed |
| 8 | 24909910 | Building the multidisciplinary team for management of patients with hepatocellular carcinoma. | Clin Gastroenterol Hepatol | 2015 | https://conductscience.org/library/papers/24909910 | PubMed |
| 9 | 29159910 | Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. | Hepatology | 2018 | https://conductscience.org/library/papers/29159910 | PubMed |
| 10 | 27072539 | Challenge of China's rural health. | BMJ | 2016 | https://conductscience.org/library/papers/27072539 | PubMed |
| 11 | 36161463 | Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. | Liver Int | 2022 | https://conductscience.org/library/papers/36161463 | PubMed |
| 12 | 31543386 | Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study. | Eur J Surg Oncol | 2019 | https://conductscience.org/library/papers/31543386 | PubMed |
| 13 | 27761414 | Controversies and evidence of hepatic resection for hepatocellular carcinoma. | BBA Clin | 2016 | https://conductscience.org/library/papers/27761414 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953582 | Psychological Stress in Hepatocellular Carcinoma: Clinical Outcomes and Biological Mechanisms. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42953582 | PubMed |
| 42757287 | Bibliometric Analysis of Gut Microbiota and Hepatocellular Carcinoma: Research Trends and Frontiers. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42757287 | PubMed |
| 42567984 | Quercetin, an ingredient of Jiedu Xiaozheng Yin, alleviates hepatocellular carcinoma progression by regulating CYP1A2/PTEN/PI3K/Akt axis. | In Vitro Cell Dev Biol Anim | 2026 | https://conductscience.org/library/papers/42567984 | PubMed |
| 42317344 | Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42317344 | PubMed |
| 42255207 | SF3B4 stabilizes SREBF1 via 3'UTR binding to drive hepatocellular carcinoma progression. | Front Oncol | 2026 | https://conductscience.org/library/papers/42255207 | PubMed |
| 42181737 | ENPP2 Dysregulation Defines a Candidate Biomarker Axis Coupling Tumor-Intrinsic cAMP Signaling to Macrophage Polarization in Hepatocellular Carcinoma. | Hum Mutat | 2026 | https://conductscience.org/library/papers/42181737 | PubMed |
| 42068148 | Association Between Multi-Laboratory Parameters Pre- and Post-Treatment and Pathological Features and Their Values in Clinical Decision in Primary Hepatic Carcinoma. | J Clin Lab Anal | 2026 | https://conductscience.org/library/papers/42068148 | PubMed |
| 41922917 | Management and outcomes of patients with liver cancer in China and the United States. | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/41922917 | PubMed |
| 41264215 | Exosomal FOSL1 From Cancer-associated Fibroblasts Drives the Progression and Pro-tumorigenic M2 Macrophage Polarization of Hepatocellular Carcinoma By Activating PLAU Transcription. | Appl Biochem Biotechnol | 2026 | https://conductscience.org/library/papers/41264215 | PubMed |
| 41121471 | Research on Anti-tumor Pharmacodynamics of Multi-functional Magnetic Lipid Polymer with Specific Targeted Transmission of siRNA and its Toxicity Evaluation. | Curr Pharm Des | 2026 | https://conductscience.org/library/papers/41121471 | PubMed |
| 40682115 | SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40682115 | PubMed |
| 40636727 | Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma. | ILIVER | 2024 | https://conductscience.org/library/papers/40636727 | PubMed |
| 40330476 | METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery. | Front Immunol | 2025 | https://conductscience.org/library/papers/40330476 | PubMed |
| 40202169 | α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study. | BJS Open | 2025 | https://conductscience.org/library/papers/40202169 | PubMed |
| 38833082 | Integrated Bioinformatic Analysis Reveals the Oncogenic, Survival, and Prognostic Characteristics of TPX2 in Hepatocellular Carcinoma. | Biochem Genet | 2025 | https://conductscience.org/library/papers/38833082 | PubMed |
| 38831828 | Apolipoprotein H-based prognostic risk correlates with liver lipid metabolism disorder in patients with HBV-related hepatocellular carcinoma. | Heliyon | 2024 | https://conductscience.org/library/papers/38831828 | PubMed |
| 38794281 | Cell-Membrane-Coated Metal-Organic Framework Nanocarrier Combining Chemodynamic Therapy for the Inhibition of Hepatocellular Carcinoma Proliferation. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38794281 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| PSEN1 | 5663 | PubTator's text mining | https://conductscience.org/library/genes/5663 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36924123
GET https://conductscience.org/api/papers/v1/36924123/authors